Australia’s best current estimate of how many people live with migraine has risen sharply to about 3.9 million, but the change does not mean the disease suddenly doubled in prevalence.

The Australian Institute of Health and Welfare now says around 14.4 per cent of Australians — roughly one in seven people — may be living with migraine.

The previous widely used estimate was about 1.7 million people, or around 6.6 to 7 per cent of the population.

The big increase comes from a change in how prevalence is estimated and from evidence that migraine has been substantially underdiagnosed and undercounted.

Why the number changed

Earlier estimates relied heavily on self-reported Australian survey data.

That approach can miss people who experience migraine but have never received a formal diagnosis, people who do not identify their symptoms as migraine, and people whose condition is not captured clearly by broad health-survey questions.

AIHW has now compared several sources and adopted 14.4 per cent as the best current prevalence estimate.

That figure comes from the Global Burden of Disease 2023 study, which combines information from many countries and uses statistical modelling to estimate prevalence where national data is incomplete.

AIHW assessed that estimate against Australian data and found it sits within a plausible range established by local sources.

The result is a more inclusive estimate of people likely to be living with migraine, not evidence of a sudden national outbreak.

Applying the 14.4 per cent estimate to Australia’s 2025 population gives about 3.9 million people.

That makes migraine the most common neurological condition included in AIHW’s current work.

AIHW estimates about 4.5 million Australians in total are living with neurological conditions, with migraine accounting for the large majority of that figure.

This does not mean everyone experiences the same severity.

Migraine can range from occasional attacks that are manageable with treatment to chronic, disabling illness that significantly affects work, study, family life and daily functioning.

AIHW estimates almost two-thirds of Australians living with migraine may not have a formal diagnosis.

That equates to close to 2.5 million people in 2025.

Undiagnosed migraine matters because people may continue treating recurrent attacks as ordinary headaches without accessing preventive medicines, specialist care or strategies that could reduce frequency and severity.

It can also distort national statistics. If prevalence is measured only by asking people whether a doctor has told them they have migraine, a large group of people with compatible symptoms will disappear from the count.

Migraine is a neurological disorder, not simply a description of severe head pain.

Attacks can involve throbbing or pulsating pain, nausea, sensitivity to light or sound, visual disturbances and neurological symptoms.

Some people experience aura before or during an attack, while others do not.

Symptoms can last for hours or days, and the condition can occur episodically or become chronic.

The pattern varies widely between individuals, which is one reason migraine is often misunderstood or minimised.

The AIHW estimate indicates migraine is more common among females than males.

Using the current modelling, around 18 per cent of females and 11 per cent of males may be living with migraine.

That works out to roughly 2.4 million females and 1.5 million males in 2025.

Hormonal factors are one reason migraine patterns can differ by sex, although genetics, sleep, stress, environment and other factors also influence attacks.

The condition is particularly common among working-age adults, meaning its impact is felt not only by the health system but also through missed work, reduced productivity and caring responsibilities.

There is no single blood test or scan that confirms most migraine cases.

Diagnosis is usually based on symptoms, medical history and the pattern of attacks, while clinicians use examinations or tests to exclude other causes when appropriate.

People may delay seeking care because they assume recurrent headaches are normal, because attacks are intermittent, or because they can temporarily manage symptoms with over-the-counter medicines.

Others may have limited access to GPs, neurologists or headache specialists.

Cost can also be a barrier, particularly for people who need repeated appointments or prescription medicines.

A disease affecting one in seven Australians looks different from a condition thought to affect about one in fourteen.

Higher prevalence estimates can influence decisions about research funding, training, specialist services, medicine access and public-health education.

Advocates argue that migraine has historically received less attention than its disability burden would justify.

AIHW’s new figures provide a stronger statistical basis for assessing that claim, but they do not automatically determine how much governments should spend or which treatments should be prioritised.

Those remain health-policy decisions that must consider effectiveness, cost and competing needs across the system.

AIHW data shows migraine accounts for a substantial share of emergency department presentations involving neurological conditions.

Emergency care may be needed when pain is severe, vomiting causes dehydration, symptoms are unusual, usual medicines fail or a person fears the headache may represent another dangerous condition.

However, emergency departments are not the ideal setting for long-term migraine management.

Better diagnosis, preventive care and treatment plans can help some people manage attacks earlier and reduce avoidable hospital visits.

The 14.4 per cent figure is AIHW’s best current estimate, not a perfect census of every Australian with migraine.

Australian data sources produce a wide range of plausible prevalence figures because surveys use different questions and definitions.

AIHW notes that the lower and upper bounds supported by Australian evidence are broad.

That uncertainty is why the institute has been explicit about the methodology rather than presenting 3.9 million as an exact count.

Future Australian-specific studies may refine the estimate again.

The Global Burden of Disease study draws on sources from many countries and uses statistical methods to estimate disease prevalence across populations.

Using an international model for Australia can seem counterintuitive, but AIHW’s reasoning is that the 14.4 per cent figure fits within the range suggested by Australian data and comes from a method designed to correct for under-diagnosis and inconsistent measurement.

That does not make the model immune from revision.

It means AIHW currently considers it the most methodologically useful estimate available.

What people with recurring headaches can take from the update

The new figures are not a reason for people to diagnose themselves solely from a statistic.

Recurring or severe headaches can have many causes, and sudden or unusual symptoms can sometimes require urgent medical assessment.

For people with a repeated pattern of headache, nausea, light or sound sensitivity, or neurological symptoms, the figures do reinforce that migraine is common and that seeking medical assessment is reasonable.

A clinician can help distinguish migraine from other headache disorders, identify triggers, review medicine use and discuss acute or preventive treatment.

People with frequent headaches may rely heavily on painkillers or migraine medicines.

Using some acute medications too often can itself contribute to medication-overuse headache, creating a cycle in which treatment becomes part of the problem.

That is another reason a long-term management plan can be more useful than repeatedly treating attacks without review.

Preventive options can include medicines, lifestyle measures and newer migraine-specific therapies depending on the person’s pattern and clinical needs.

The key takeaway

Australia has not suddenly experienced a doubling of migraine cases.

What has changed is the way experts estimate how many people are living with the condition.

AIHW now considers 14.4 per cent — about 3.9 million Australians in 2025 — the best current estimate, with close to 2.5 million potentially living without a formal diagnosis.

The higher number reflects better recognition of undercounting and methodological limits in earlier surveys.

For patients, the practical message is that migraine is common, often underdiagnosed and capable of causing significant disability. For policymakers, the new estimate raises a straightforward question: whether health services, research and public understanding are scaled to a condition that may affect roughly one in seven Australians.

Prevalence data influences what doctors and patients consider normal or worth investigating. If migraine is understood to affect roughly one in seven Australians, recurring symptoms may be taken more seriously by patients, employers and clinicians. That does not mean every headache is migraine, but it can reduce the tendency to dismiss repeated attacks as something people simply have to tolerate. More accurate prevalence also gives researchers a better denominator for measuring treatment access, diagnosis gaps and health-service use over time.